Fatigue is the most common symptom of MS and has no effective pharmacotherapy.
Objective:
To determine the tolerability, safety, and efficacy of low-dose ketamine infusion for MS-related fatigue.
Methods:
In this double-blind, randomized, active-placebo-controlled trial, 18 subjects with multiple sclerosis (MS) and reported fatigue received a single intravenous infusion of ketamine (0.5 mg/kg) or midazolam (0.05 mg/kg). The primary outcome was change in Daily Fatigue Severity (DFS) for 7 days following the infusion. Secondary outcomes included Fatigue Severity Scale (FSS) and Modified Fatigue Impact Scale (MFIS) measured up to day 28 post-infusion. We analyzed changes in all outcomes using mixed-effect models.
Results:
In total, 18 participants were enrolled; 67% participants received ketamine. Side effects of ketamine were transient. No change in the DFS was observed after 7 days (−0.10 point; 95% confidence interval (CI): −0.32, 0.12; p = 0.40). We observed a trend in reduced FSS scores at 1 week (−5.2 points; 95% CI: −10.4, 0.14; p = 0.06) and a clinically and statistically significant reduction in MFIS score at day 28 (−13.5 point; 95% CI: −25.0, −1.98; p = 0.04).
Conclusions:
Ketamine infusions were safe and well-tolerated. While no change in DFS after 7 days was observed, secondary analyses suggest a benefit of ketamine infusion for reduction of longer term fatigue severity in people with MS.
KruppL.Fatigue is intrinsic to multiple sclerosis (MS) and is the most commonly reported symptom of the disease. Mult Scler2006; 12(4): 367–368.
2.
LerdalACeliusEGKruppL, et al. A prospective study of patterns of fatigue in multiple sclerosis. Eur J Neurol2007; 14(12): 1338–1343.
3.
JanardhanVBakshiR.Quality of life in patients with multiple sclerosis: The impact of fatigue and depression. J Neurol Sci2002; 205(1): 51–58.
4.
BlaneyDBELowe-StrongA. The impact of fatigue on communication in multiple sclerosis. The insider’s perspective. Disabil Rehabil2009; 31(3): 170–180.
5.
SmithMMArnettPA.Factors related to employment status changes in individuals with multiple sclerosis. Mult Scler2005; 11(5): 602–609.
6.
ToosyACiccarelliOThompsonA.Symptomatic treatment and management of multiple sclerosis. Handb Clin Neurol2014; 122: 513–562.
7.
BraleyTJChervinRD.Fatigue in multiple sclerosis: Mechanisms, evaluation, and treatment. Sleep2010; 33(8): 1061–1067.
8.
NourbakhshBRevirajanNWaubantE.Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple sclerosis (TRIUMPHANT-MS): Study design for a pragmatic, randomized, double-blind, crossover clinical trial. Contemp Clin Trials2018; 64: 67–76.
9.
GottschalkMKümpfelTFlacheneckerP, et al. Fatigue and regulation of the hypothalamo-pituitary-adrenal axis in multiple sclerosis. Arch Neurol2005; 62(2): 277–280.
10.
GoldSMKrügerSZieglerKJ, et al. Endocrine and immune substrates of depressive symptoms and fatigue in multiple sclerosis patients with comorbid major depression. J Neurol Neurosurg Psychiatry2011; 82(7): 814–818.
11.
DantzerRO’ConnorJCFreundGG, et al. From inflammation to sickness and depression: When the immune system subjugates the brain. Nat Rev Neurosci2008; 9(1): 46–56.
12.
HankenKElingPHildebrandtH.The representation of inflammatory signals in the brain—A model for subjective fatigue in multiple sclerosis. Front Neurol2014; 5: 264.
13.
PowellDJHMoss-MorrisRLiossiC, et al. Circadian cortisol and fatigue severity in relapsing-remitting multiple sclerosis. Psychoneuroendocrinology2015; 56: 120–131.
14.
HeesenCNawrathLReichC, et al. Fatigue in multiple sclerosis: An example of cytokine mediated sickness behaviour?J Neurol Neurosurg Psychiatry2006; 77(1): 34–39.
15.
VeauthierCHasselmannHGoldSM, et al. The Berlin treatment algorithm: Recommendations for tailored innovative therapeutic strategies for multiple sclerosis-related fatigue. EPMA J2016; 7: 25.
16.
PellicanoCGalloALiX, et al. Relationship of cortical atrophy to fatigue in patients with multiple sclerosis. Arch Neurol2010; 67(4): 447–453.
17.
YaldizliÖPennerI-KFrontzekK, et al. The relationship between total and regional corpus callosum atrophy, cognitive impairment and fatigue in multiple sclerosis patients. Mult Scler2014; 20(3): 356–364.
18.
SepulcreJMasdeuJCGoñiJ, et al. Fatigue in multiple sclerosis is associated with the disruption of frontal and parietal pathways. Mult Scler2009; 15(3): 337–344.
19.
FinkeCSchlichtingJPapazoglouS, et al. Altered basal ganglia functional connectivity in multiple sclerosis patients with fatigue. Mult Scler2015; 21(7): 925–934.
20.
PravatàEZeccaCSestieriC, et al. Hyperconnectivity of the dorsolateral prefrontal cortex following mental effort in multiple sclerosis patients with cognitive fatigue. Mult Scler2016; 22(13): 1665–1675.
21.
NourbakhshBRevirajanNWaubantE.Association Between Glutamate Blockade and Fatigue in Patients With Multiple Sclerosis. JAMA Neurol2015; 72(11): 1374–1375.
22.
Peyro Saint PaulLCreveuilCHeinzlefO, et al. Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study. J Neurol Sci2016; 363: 69–76.
23.
LoveraJFFrohmanEBrownTR, et al. Memantine for cognitive impairment in multiple sclerosis: A randomized placebo-controlled trial. Mult Scler2010; 16(6): 715–723.
24.
VillosladaPArrondoGSepulcreJ, et al. Memantine induces reversible neurologic impairment in patients with MS. Neurology2009; 72(19): 1630–1633.
25.
ZarateCASinghJBCarlsonPJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry2006; 63(8): 856–864.
26.
AbdallahCGDe FeyterHMAverillLA, et al. The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects. Neuropsychopharmacology2018; 43(10): 2154–2160.
27.
ZanosPGouldTD.Mechanisms of ketamine action as an antidepressant. Mol Psychiatry2018; 23(4): 801–811.
28.
SaliganLNFarmerCBallardED, et al. Disentangling the association of depression on the anti-fatigue effects of ketamine. J Affect Disord2019; 244: 42–45.
29.
KroenckeDCLynchSGDenneyDR.Fatigue in multiple sclerosis: Relationship to depression, disability, and disease pattern. Mult Scler2000; 6(2): 131–136.
FlacheneckerPKümpfelTKallmannB, et al. Fatigue in multiple sclerosis: A comparison of different rating scales and correlation to clinical parameters. Mult Scler2002; 8(6): 523–526.
32.
RooneySMcFadyenDAWoodDL, et al. Minimally important difference of the fatigue severity scale and modified fatigue impact scale in people with multiple sclerosis. Mult Scler Relat Disorders2019; 35: 158–163.
33.
KlugerBMGarimellaSGarvanC.Minimal clinically important difference of the Modified Fatigue Impact Scale in Parkinson’s disease. Parkinsonism Relat Disord2017; 43: 101–104.
34.
Riva-PossePReiffCMEdwardsJA, et al. Blood pressure safety of subanesthetic ketamine for depression: A report on 684 infusions. J Affect Disord2018; 236: 291–297.
35.
ChalahMAAyacheSS.Cognitive behavioral therapies and multiple sclerosis fatigue: A review of literature. J Clin Neurosci2018; 52: 1–4.
36.
WilkinsonSTFarmerCBallardED, et al. Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant. Neuropsychopharmacology2019; 44(7): 1233–1238.
